EDIT-401 CRISPR therapy enters clinical trials; safety data set for 2027
EDIT advances in vivo CRISPR therapy EDIT-401 to reduce LDL cholesterol by upregulating LDLR in the liver. Phase I begins in Australia, with safety data expected in early 2027 and U.S. entry planned for 2027.
The company is advancing in vivo CRISPR therapies, with EDIT-401 aimed at lowering LDL cholesterol by upregulating LDLR in the liver. S. entry planned for the same year. Cash reserves support operations through…